<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191030045275N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-02</date_registration>
      <primary_sponsor>Faculty of Medicine, Tanta University</primary_sponsor>
      <public_title>Corn oil for gastric wash in acute aluminum phosphide poisoning</public_title>
      <acronym></acronym>
      <scientific_title>Corn oil for gastric decontamination in acute aluminum phosphide poisoning: A randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>98</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48103</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We used the sealed, opaque sequentially numbered envelopes method for randomization and allocation concealment of patients included in this trial as described by Doig and Simpson (2005). We used 98 identical, opaque, letter-sized envelopes. We used 2 rolls of household aluminum cooking foil that we cut into 98 sheets (of the same width as and twice the height of the envelope). We prepared 98 envelope-sized sheets of white paper and 98 envelope-sized sheets of single sided carbon paper. We wrote “Treatment A” on 49 paper sheets and “Treatment B” on the other 49 sheets. To prepare 49 Treatment A envelops, we selected one envelope-sized sheet of of Treatment A and placed one sheet of carbon paper on top of the Treatment A allocation paper with the carbon side facing the paper, then we put both papers inside a foil wrapper. Then, the completed insert was placed into a blank envelope with the carbon paper closest to the front of the envelope. Finally, the envelop was sealed and we signed across the seal. We completed all the 49 Treatment A envelops the same way. We prepared 49 Treatment B envelops the same way as Treatment A envelops. Both sets of envelops were combined and we shuffled them thoroughly. Then, using a pen we marked a number on the front of each envelope sequentially from 1 to 98. The carbon paper inside the envelope will transfer this number to the allocation paper inside. Finally, we placed these envelopes into a plastic container, in numerical order, ready for use.

Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care 2005;20:187–93, Blinding description: Only participants will be masked. We will achieve this by making a letter for each medication used and masking the name of the medication.</study_design>
      <phase>2</phase>
      <hc_freetext>Acute aluminum phosphide poisoning.</hc_freetext>
      <i_freetext>Intervention 1: Control group (Sodium bicarbonate): Patients will receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, adequate hydration, and supportive treatment. Gastric decontamination will be carried out through aspiration of gastric contents via a nasogastric tube using 60 ml syringe.Then, gastric lavage will be performed using sodium bicarbonate. Intervention 2: Intervention group (Corn oil): Patients will receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, adequate hydration, and supportive treatment. Gastric decontamination will be carried out through aspiration of gastric contents via a nasogastric tube using 60 ml syringe. Then, 60 ml  of corn oil will be administered following aspiration of gastric contents.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
We plan to share all IPD that underlie results

When:
Data will become available 6 months and ending 36 months following article publication

To whom:
Researchers from academic institutions whose proposal for the use of data has been approved by an independent review committee identified for this purpose

Conditions:
For IPD meta-analysis

Where to obtain:
Data will be obtainable from the PI

How to obtain:
A proposal for the use of data to be submitted to the PI, then evaluated by an independent review committee identified for this purpose

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Fatma Elgazzar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>El-Giesh Street, Medical Campus of the Faculty of Medicine, Tanta University</address>
        <city>Tanta</city>
        <country1>Egypt</country1>
        <zip>31527</zip>
        <telephone>+20 40 3350373</telephone>
        <email>fm.elgazzar@gmail.com</email>
        <affiliation>Faculty of Medicine, Tanta University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Prof. Ahmad El-Ebiary</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>El-Giesh Street, Medical Campus of the Faculty of Medicine, Tanta University</address>
        <city>Tanta</city>
        <country1>Egypt</country1>
        <zip>31527</zip>
        <telephone>+20 40 3350373</telephone>
        <email>a.ebiary@med.tanta.edu.eg</email>
        <affiliation>Faculty of Medicine, Tanta University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Egypt</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ingestion of aluminum phosphide
presentation to the hospital within two hours of aluminum phosphide ingestion</inclusion_criteria>
      <agemin>12 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>vomiting within one hour after aluminum phosphide ingestion
dissolving the aluminum phosphide pill(s) in water prior to ingestion
ingestion of or exposure to substances other than aluminum phosphide
treatment for aluminum phosphide poisoning in other medical facilities before admission
pregnancy
lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T60</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Toxic effect of pesticides</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group (Sodium bicarbonate): Patients will receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, adequate hydration, and supportive treatment. Gastric decontamination will be carried out through aspiration of gastric contents via a nasogastric tube using 60 ml syringe.Then, gastric lavage will be performed using sodium bicarbonate.</i_keyword>
      <i_keyword>Intervention group (Corn oil): Patients will receive the standard treatment, which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, adequate hydration, and supportive treatment. Gastric decontamination will be carried out through aspiration of gastric contents via a nasogastric tube using 60 ml syringe. Then, 60 ml  of corn oil will be administered following aspiration of gastric contents.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>All-cause mortality during hospital admission. Timepoint: At the end of the hospitalization period. Method of measurement: Clinical assessment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Proportion of patients requiring intubation. Timepoint: At the end of the hospitalization period. Method of measurement: Clinical evaluation.</sec_outcome>
      <sec_outcome>Duration of ventilation. Timepoint: At the end of the hospitalization period. Method of measurement: Clinical evaluation.</sec_outcome>
      <sec_outcome>Duration of hospital stay. Timepoint: At the end of the hospitalization period. Method of measurement: Clinical evaluation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The investigators</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-04-24</approval_date>
        <contact_name>Ethics Committee of Tanta Faculty of Medicine</contact_name>
        <contact_address>El-Giesh Street, Medical Campus of the Faculty of Medicine, Tanta University Tanta El-Gharbia Egypt</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
